Drug intelligence / Profile preview

mallotusinic acid

Development stage: Preclinical
Modality: Small Molecules

Overview

Mallotusinic acid is a hydrolyzable ellagitannin belonging to the dehydrohexahydroxydiphenoyl (DHHDP) group, naturally occurring in plants such as *Mallotus japonicus* and *Acer pseudosieboldianum*. It has demonstrated significant chemopreventive, anti-proliferative, and pro-apoptotic activities, particularly in prostate cancer cell models. The compound functions as an epigenetic modulator by inhibiting DNA methyltransferases, specifically DNMT1, DNMT3a, and DNMT3b. This inhibition facilitates the demethylation and subsequent re-expression of tumor suppressor genes, such as glutathione S-transferase P1 (GSTP1), which are frequently silenced during the progression of prostate cancer.

Targets

DNMT1 (DNA (cytosine-5)-methyltransferase 1)DNMT3A (DNA methyltransferase 3 alpha)DNMT3B (DNA (cytosine-5)-methyltransferase 3B)

Beyond the preview

Go deeper on mallotusinic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mallotusinic acid.

Explore the full profile